INSM Insmed Incorporated

NASDAQ
$129.41

Insmed Incorporated (INSM) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with INSM's own trailing one-year pace, with 49% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 6 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
7
58 transactions
Purchases
$0
0 shares
Sales
$82.1M
624,395 shares
Net activity
-$82.1M
purchases less sales

How much of that selling was preplanned? 49% planned / 51% discretionary

10b5-1 plan sales $40.1M 44 transactions · 298,086 shares
Discretionary sales $42.0M 14 transactions · 326,309 shares

Largest single sale: $32.0M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Brennan David R Director Sell 25,000 $124.00 $3.1M 39,238 −38.9% of holding
SHAROKY MELVIN MD Director Sell 5,000 $127.53 $637.7K None left
Adsett Roger Chief Operating Officer Sell 239,850 $133.27 $32.0M 98,744 −70.8% of holding
Flammer Martina M.D. 2 fills Chief Medical Officer Sell 10b5-1 27,173 $128.61 $3.5M 78,764 −25.7% of holding
Lewis William 2 fills Chair and CEO Sell 10b5-1 10,700 $106.06 $1.1M 264,930 −3.9% of holding
Lewis William 3 fills Chair and CEO Sell 10b5-1 10,699 $117.40 $1.3M 264,752 −3.9% of holding
Flammer Martina M.D. 2 fills Chief Medical Officer Sell 10b5-1 12,302 $109.98 $1.4M 67,934 −15.3% of holding
Lewis William 5 fills Chair and CEO Sell 10b5-1 21,398 $103.32 $2.2M 268,224 −7.4% of holding
Smith Michael Alexander Chief Legal Officer Sell 10b5-1 1,806 $95.82 $173.1K 37,648 −4.6% of holding
Lewis William Chair and CEO Sell 10b5-1 6,515 $94.03 $612.6K 258,917 −2.5% of holding
Flammer Martina M.D. Chief Medical Officer Sell 10b5-1 1,858 $103.78 $192.8K 60,486 −3% of holding
Lewis William Chair and CEO Sell 7,605 $102.27 $777.8K 265,432 −2.8% of holding
Flammer Martina M.D. Chief Medical Officer Sell 2,566 $102.27 $262.4K 62,344 −4% of holding
Bonstein Sara Chief Financial Officer Sell 2,404 $102.27 $245.9K 69,082 −3.4% of holding
Adsett Roger Chief Operating Officer Sell 2,370 $102.27 $242.4K 98,603 −2.3% of holding
Smith Michael Alexander Chief Legal Officer Sell 2,159 $102.27 $220.8K 39,454 −5.2% of holding
Smith Michael Alexander Chief Legal Officer Sell 10b5-1 6,149 $108.47 $667.0K 41,613 −12.9% of holding
Lewis William 3 fills Chair and CEO Sell 10b5-1 25,564 $106.33 $2.7M 292,848 −8% of holding
Flammer Martina M.D. Chief Medical Officer Sell 10b5-1 10,479 $117.54 $1.2M 64,910 −13.9% of holding
Lewis William Chair and CEO Sell 13,283 $116.18 $1.5M 287,902 −4.4% of holding
Bonstein Sara Chief Financial Officer Sell 8,272 $116.18 $961.0K 71,486 −10.4% of holding
Flammer Martina M.D. 2 fills Chief Medical Officer Sell 7,854 $114.23 $897.2K 78,773 −9.1% of holding
Adsett Roger Chief Operating Officer Sell 5,837 $116.18 $678.1K 100,973 −5.5% of holding
Smith Michael Alexander Chief Legal Officer Sell 4,109 $116.18 $477.4K 47,762 −7.9% of holding
Flammer Martina M.D. 2 fills Chief Medical Officer Sell 10b5-1 12,949 $100.40 $1.3M 84,073 −13.3% of holding
Lewis William 6 fills Chair and CEO Sell 10b5-1 10,699 $137.34 $1.5M 311,451 −3.3% of holding
Lewis William 4 fills Chair and CEO Sell 10b5-1 10,699 $143.97 $1.5M 309,638 −3.3% of holding
Lewis William 3 fills Chair and CEO Sell 10b5-1 10,699 $163.22 $1.7M 311,097 −3.3% of holding
Adsett Roger 3 fills Chief Operating Officer Sell 10b5-1 88,060 $164.63 $14.5M 188,155 −31.9% of holding
Smith Michael Alexander Chief Legal Officer Sell 10b5-1 19,638 $150.98 $3.0M 51,871 −27.5% of holding
Lewis William 3 fills Chair and CEO Sell 10b5-1 10,699 $143.52 $1.5M 310,255 −3.3% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.